



ABSTRACT

The present invention is directed to a method of inhibiting the progression or development of type 1 diabetes in a mammal having type 1 diabetes or at risk for type 1 diabetes. The method comprises administering to the mammal a pharmaceutical composition comprising an agent that inhibits a macrophage migration inhibitory factor (MIF) in the mammal, wherein the agent comprises a binding site of an antibody that binds specifically to the MIF.